EUROASPIRE II2 - One in five heart patients continue to smoke after first coronary event
Oct 6, 2005 - 10:59:00 PM
|
|
|
"We found that younger patients were less likely to quit smoking only 41% of under 50s and that those with angina were less likely to quit than those who had suffered a heart attack (38% as against 52%)"
|
By European Heart Journal,
[RxPG] An international survey published today (Thursday 6 October) in Europe's leading cardiology journal, European Heart Journal1, reveals that fewer than half of the heart patients in the study who smoked quit after suffering their first coronary event, with one out of five continuing to smoke despite advice to stop.
Epidemiologist and lead author of the study, Dr Wilma Scholte op Reimer, said it was "unbelievable" that so many carried on smoking after a life-threatening event for which smoking is a major risk factor. "It makes me wonder if they are truly aware of the risk that they are taking," she said.
The survey EUROASPIRE II2 undertaken during 1999 and 2000, involved 5,551 coronary patients aged up to 70 in 47 hospitals in 15 European countries. They were interviewed around 16 months after the event or condition for which they entered hospital coronary artery bypass, balloon angioplasty, heart attack or unstable angina. The patients were asked if they had ever smoked, whether they had smoked in the month prior to hospital admission and whether they currently smoked, with smokers who denied currently smoking being tested for carbon monoxide in their breath. The survey was a follow-up to EUROASPIRE I five years earlier and found similar results.
Of the 5,551 patients, 21% were still persistent smokers 39% of those under 50, 26% of those aged 50-60 and 14% of those aged around 60. Men and women had similar prevalence. Nearly all (99%) of the 2,244 pre-heart event smokers had been advised by a health professional to stop, and 48% had done so.
"We found that younger patients were less likely to quit only 41% of under 50s and that those with angina were less likely to quit than those who had suffered a heart attack (38% as against 52%)," said Dr Scholte op Reimer who works at the Erasmus University Medical Centre in Rotterdam, The Netherlands.
The worrying finding that those with angina were less likely to stop than heart attack patients may be due to a lack of awareness of their risk, according to Dr Scholte op Reimer. A heart attack was often the first manifestation of coronary disease. Doctors were keen on achieving good risk management in these cases and the patients themselves were motivated because they probably realised the seriousness of their diseases.
However, for angina patients, the risk may have been under-estimated. "In fact, their long term mortality is no better than that of patients who have had a heart attack," she said. "Perhaps this needs to be spelled out to them. The need to stop is highest in patients with established coronary heart disease (CHD) as within two to three years the risk of subsequent events falls to that of CHD patients who have never smoked. In people with no symptoms it takes up to ten years for risks to fall to the level of non-smokers. This shows how much a patient can gain from quitting often much more than most of the medication they take. I think professionals should confront their patients with these facts more often."
Another surprising finding was that only one fifth of those who had stopped reported having received written advice compared with 30% of those who continued smoking. "We can't tell from our study why this is," said Dr Scholte op Reimer. "Perhaps most patients who stopped had already made the decision when the written advice was given to them and therefore didn't register it, or maybe the advice was offered or put out for them to take away, but having decided to stop smoking, not accepted because they felt no need to take it."
The survey showed there was still a need for the development of more intensive, effective smoking cessation programmes, particularly focused on younger patients, those with lower levels of education (who the survey found were less likely to stop than those with university education) and those whose disease had first manifested as angina.
Dr Scholte op Reimer said that, in line with current guidelines on cardiovascular disease (CVD) prevention, a doctor's firm advice at the time of diagnosis was the most important factor in starting the quitting process. Many patients succeeded without special programmes, but for those who needed support, there should be a specific plan that is followed through. Nicotine replacement and certain anti-depressants should also be available if necessary.
There may also be a difference, she said, between patients having the general knowledge that smoking is a bad habit, and learning their precise risk as an individual. Individual risk could now be worked out via HeartScore a computer program launched recently by the European Society of Cardiology, aimed at preventing CVD (primary prevention). The program can also calculate how much a person can change his or her risk of fatal CVD within 10 years by stopping smoking.
Another survey EUROASPIRE III is planned to see whether the situation improves. "It was disappointing that there was hardly any change in the five years between the first two surveys. However, we believe that the European guidelines on CVD prevention, tools such as HeartScore and interventions by governments might mean that attitudes will have improved by the time we carry out the next survey," Dr Scholte op Reimer concluded.
Publication:
The European Heart Journal - official journal of the European Society of Cardiology
On the web:
www.escardio.org 
|
Advertise in this space for $10 per month.
Contact us today.
|
 |
|
Subscribe to CAD Newsletter
|
|
|
|
Additional information about the news article
|
Reference:
1 Smoking behaviour in European patients with established coronary heart disease. European Heart Journal. doi:10.1093/eurheartj/ehi497.
2 EUROASPIRE (European Action on Secondary Prevention through Intervention to Reduce Events). The 15 countries taking part in EUROASPIRE II were: Belgium, Czech Republic, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Netherlands, Poland, Slovenia, Spain, Sweden, UK. Results for individual countries are included in the paper.
The European Heart Journal is an official journal of the European Society of Cardiology. Please acknowledge the journal as a source in any articles. Paper available on request.
|
|
Feedback
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
|
Top of Page
|
